Prognosis
Pfizer Studies 3-Dose Covid Shot for Young Kids as Parents Wait
- Three shots looking more like the standard fare of the future
- Pfizer lifts forecast for vaccine’s 2022 sales to $31 billion
This article is for subscribers only.
Pfizer Inc. and BioNTech SE plan to study a three-dose regimen of their Covid-19 vaccine in young children 6 months to 4 years old, a move that may extend the wait for anxious parents as fast-spreading variants complicate clinical trials.
When tested in children ages 2 to 4, the two-shot regimen failed to meet a laboratory standard for immune response set in an older age group, according to a statement. The vaccine partners said they amended their clinical trial protocol following a request by an external, independent data-monitoring committee. No safety concerns were identified among the young children.